The United States Food and Drug Administration inspected Alembic Pharmaceuticals’ Solid Oral Formulation Facility (F-4) at Jarod.
The scheduled GMP inspection was conducted from November 14, 2024, to November 22, 2024. The USFDA issued a Form 483 with five procedural observations.